Clinical trial · Observational
Evaluation of MG53 (TRIM72) Levels in Women With Polycystic Ovary Syndrome: An Observational Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Purpose of the Study: This study is being conducted to examine a protein called MG53 (also known as TRIM72) in women with polycystic ovary syndrome (PCOS). MG53 is involved in cell membrane repair and may play a role in insulin resistance, which is common in PCOS. Study Procedures: Women between 18 and 45 years of age will be invited to participate. The study population will include both women diagnosed with PCOS and healthy controls. A single blood sample (approximately 5 mL) will be collected from each participant. MG53 levels will be measured using an ELISA laboratory assay. Significance of the Study: Analysis of MG53 levels in relation to hormonal and metabolic markers may help determine whether MG53 is associated with insulin resistance and other characteristics of PCOS.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Insulin Resistance Syndrome | — | UNRESOLVED | — |
| Polycystic Ovary Syndrome (PCOS) | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| No intervention (observational study) | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- PCOS Group
- description
- Women aged 18-45 years diagnosed with polycystic ovary syndrome (PCOS) based on Rotterdam criteria. A single blood sample is collected for MG53 and routine metabolic markers. No intervention is applied.
- interventionNames
- Other: No intervention (observational study)
- label
- Healthy Controls
- description
- Women aged 18-45 years without PCOS or other chronic conditions. A single blood sample is collected for MG53 and routine metabolic markers. No intervention is applied.
- interventionNames
- Other: No intervention (observational study)
Primary outcomes (1)
- measure
- Serum MG53 level
- timeFrame
- Baseline (single time point at enrollment)
- description
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 45 Years
Show eligibility criteria text
Inclusion Criteria: * Female participants aged 18 to 45 years * Diagnosed with polycystic ovary syndrome (PCOS) according to Rotterdam criteria or healthy controls without PCOS * Able and willing to provide informed consent Exclusion Criteria: Currently pregnant * Presence of chronic systemic disease * Use of metformin or any hormonal treatment
References
Publications (1)
- DERIVEDCoskun ES, Gencer FK, Salman S, Nurlu N, Bacak HB, Kumbasar S, Timur GY, Celikoglu E, Unlu S, Tunccag F, Guven R. Decreased serum MG53 levels are associated with SHBG and androgen excess in women with polycystic ovary syndrome. Sci Rep. 2026 Apr 13;16(1):15753. doi: 10.1038/s41598-026-48800-z. PMID 41974999